Aspire BioPharma is trading 7.4% up at $6.21 today, likely fueled by positive sentiment stemming from the company's recent definitive agreement to acquire Dura Driver Control Systems for $30 million announced on June 12, 2026.
- This acquisition, expected to close in Q3 2026, is set to significantly diversify Aspire's revenue into automotive control systems with Dura generating over $200 million in 2025 revenue.
- The stock continues its recent choppy trend, fluctuating within the mid-$5 to low-$6 range over several volatile sessions.
- While no new major company-specific news was released on July 9, 2026, other recent corporate actions include a $5.0 million share repurchase program and a successful pre-IND meeting with the FDA earlier in the year.